migalastat HCl 150 mg

DRUG5 trials

Sponsors

Amicus Therapeutics

Conditions

Fabry Disease

Phase 3

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

CompletedNCT02194985

Amicus TherapeuticsFabry Disease

Start: 2015-03-14End: 2019-10-23Updated: 2020-12-21

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

CompletedNCT03500094

Amicus TherapeuticsFabry Disease

Start: 2018-09-27End: 2021-02-06Updated: 2021-11-30

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Active, not recruitingNCT04020055

Amicus TherapeuticsFabry Disease

Start: 2022-10-31End: 2026-12-31Target: 14Updated: 2026-07-06

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

CompletedNCT04049760

Amicus TherapeuticsFabry Disease

Start: 2019-10-11End: 2024-11-29Updated: 2026-02-05

Unknown Phase

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Amicus TherapeuticsFabry Disease

Updated: 2025-07-03

Related Papers

Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension

Molecular Genetics and Metabolism2025-04-043 citations

Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment

PLoS ONE2024-12-054 citations

Assessment of plasma lyso-Gb<sub>3</sub> for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.

2020-09-3038 citations

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.

2019-12-3011 citations